Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration: A Randomized, Multicentre, Controlled Trial

NCT06180382 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Saint Etienne as lead sponsor.

NCT NCT06180382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06180382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration: A Randomized, Multicentre, Controlled Trial
Lead sponsor
Centre Hospitalier Universitaire de Saint Etienne
Phase
Phase 4
Overall status
Recruiting
Start date
October 31, 2024
Completion date
October 31, 2028
Enrollment
220 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease